Silke Kapp-Schwoerer

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction.

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction.

Journal: HemaSphere

Published: February 02, 2025

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

Journal: HemaSphere

Published: August 31, 2024

Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.

Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.

Journal: Nature communications

Published: April 12, 2024

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

Journal: Journal of hematology & oncology

Published: May 30, 2023

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Haematology

Published: February 26, 2023

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting.

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting.

Journal: Pathogens (Basel, Switzerland)

Published: March 01, 2022

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.

Journal: Expert opinion on pharmacotherapy

Published: February 23, 2022

Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG.

Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG.

Journal: Pathogens (Basel, Switzerland)

Published: December 29, 2021

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin.

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin.

Journal: Haematologica

Published: May 28, 2021

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Journal: Blood

Published: April 06, 2020

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 19, 2019

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Journal: Blood

Published: May 03, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026